Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaginal microbicides

This article was originally published in The Tan Sheet

Executive Summary

Researchers at the University of California-San Francisco announce they are seeking women aged 18 to 24 to participate in the first U.S. safety study of a vaginal microbicide to prevent herpes and HIV infection. VivaGel (3% w/w SPL7013) is designed to prevent herpes and HIV infection through the use of a dendrimer molecule. Herpes and HIV molecules are "caught" in the dendrimer branches and prevented from entering and infecting human cells, lead researcher Anna-Barbara Moscicki, MD, says Nov. 29. In related news, the Canadian government announces Dec. 1 a $13.2 mil. donation to the International Partnership for Microbicides to support product development and clinical trials of microbicides for women in developing countries. In August, the Global HIV Prevention Working Group issued a report encouraging increased manufacturing of microbicides to meet public need (1"The Tan Sheet" Aug. 21, 2006, p.7)...

You may also be interested in...



Microbicide Manufacturing Capacity Ramp-Up Urged In HIV Report

Development of sufficient manufacturing capacities for microbicides will likely need to begin years in advance of regulatory approval in order to meet public health needs, an HIV prevention working group says

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel